You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:
Business Description: ImpediMed Limited (IPD) develops bioimpedance devices with a focus on medical applications for use in a variety of healthcare segments. These products have a range of potential commercial applications, notably in the assessment and monitoring of secondary lymphedema, general health assessment and weight management, muscle wasting, drug dosing and monitoring and sports medicine and fitness.
Strategy Analysis: IPD plans a number of milestones for the coming year: build reimbursement coverage for the CPT-0239T code to support increasing demand ; expand clinical acceptance of the L-Dex technology and drive testing demand with key medical providers and governing societies; secure FDA clearance for the unilateral limb claim for L-Dex U400; launch the Stanford University School of Medicine registry; continue to build and publish outcomes data on the benefits of early detection/ intervention in breast cancer patients; establish a new BIS distribution channel in Germany; and meet key commercialisation milestones for the UB500.
ImpediMed reported NPAT of $5.94m for the half-year ended 31 December 2011. Revenues from ordinary activities were $1.49m, down 25% from the same period last year. Basic and diluted EPS were (4) cents compared to (6) cents last year. The net operating cash outflow was $6.23m compared to an outflow of $5.91m in the pcp. No dividend was declared. ImpediMed reported NPAT of $5.94m for the half-year ended 31 December 2011. Revenues from ordinary activities were $1.49m, down 25% from the same period last year. Basic and diluted EPS were (4) cents compared to (6) cents last year. The net operating cash outflow was $6.23m compared to an outflow of $5.91m in the pcp. No dividend was declared.
The Age 18/05/2013 |
As Australia's major retailers increase their online sales channels, pouring millions into their websites, they could face new competition from China's booming e-commerce industry.
The Age 18/05/2013 |
Most of those who take a political approach to the budget assume that if it's in deficit, the way you get it back to surplus is to cut government spending or, if you're a really bad person, increase taxes. They forget it's the budget itself that's supposed to do the heavy lifting.
IMPORTANT: This information has been prepared without taking into account your objectives, financial situation or needs and you should consider if the information is appropriate for you before making an investment decision. Neither InvestSMART Financial Services Pty Ltd nor any of its Related Companies make any recommendations as to the merits of any investment opportunity referred to in its emails or its related websites. Product disclosure statements for financial products offered through InvestSMART can be downloaded from this website or obtained by contacting 1300 880 160. You should consider the product disclosure statement before making a decision about the product. All indications of performance returns are historical and can not be relied upon as an indicator for future performance.